7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 
      
    		                          
      revenues:
    		                          
      net product revenue
    		108,111,000 71,501,000 36,739,000                        
      license and services revenue
    		8,311,000 37,440,000 79,894,000        1,826,000 1,775,000 338,000 73,746,000             
      royalty revenue
    		4,278,000 1,624,000                         
      total revenues
    		120,700,000 110,565,000 116,633,000                        
      operating costs and expenses:
    		                          
      cost of revenues:
    		                          
      cost of goods sold
    		4,028,000 2,848,000 2,034,000                        
      cost of license, services and royalty revenue
    		2,535,000 805,000                         
      total cost of revenues
    		6,563,000 3,653,000 2,639,000                        
      research and development
    		112,874,000 111,231,000 111,431,000 130,350,000 120,444,000 114,695,000 140,972,000 130,226,000 125,136,000 107,488,000 92,861,000 90,902,000 92,511,000 108,400,000 107,649,000 122,200,000 104,305,000 101,960,000 122,559,000 90,174,000 92,050,000 86,598,000 68,225,000 57,485,000 55,278,000 52,331,000 
      selling, general and administrative
    		137,621,000 129,154,000 106,365,000 94,782,000 68,819,000 59,523,000 65,807,000 47,583,000 35,777,000 36,122,000 31,108,000 31,862,000 31,188,000 36,426,000 43,713,000 54,749,000 46,084,000 45,970,000         
      restructuring, impairment and related charges
    		8,841,000 805,000 570,000 4,693,000 4,621,000 2,891,000 3,400,000 754,000 272,000 3,531,000 3,369,000 7,691,000 5,016,000 8,396,000 22,662,000            
      total operating costs and expenses
    		265,899,000 244,843,000 221,005,000 231,909,000 194,482,000 177,707,000 210,777,000 179,161,000 161,783,000 147,740,000 127,989,000 131,102,000 129,454,000 153,922,000 175,372,000 178,500,000 151,843,000 148,039,000         
      income from operations
    		-145,199,000 -134,278,000 -104,372,000 -226,027,000 -191,750,000 -175,539,000 343,000 -177,416,000 -157,692,000 -146,099,000 -126,163,000 -129,232,000 -129,116,000 -80,176,000 -173,678,000 -165,614,000 -149,499,000 -94,015,000 -167,504,000 -127,489,000 -119,939,000 -124,567,000 -102,487,000 -78,638,000 -54,532,000 -69,249,000 
      yoy
    		-24.28% -23.51% -30529.15% 27.40% 21.60% 20.15% -100.27% 37.28% 22.13% 82.22% -27.36% -21.97% -13.63% -14.72% 3.69% 29.90% 24.65% -24.53% 63.44% 62.12% 119.94% 79.88%     
      qoq
    		8.13% 28.65% -53.82% 17.88% 9.23% -51277.55% -100.19% 12.51% 7.94% 15.80% -2.37% 0.09% 61.04% -53.84% 4.87% 10.78% 59.02% -43.87% 31.39% 6.29% -3.72% 21.54% 30.33% 44.21% -21.25%  
      operating margin %
    		   -3842.69% -7018.67% -8096.82% 0.16% -10167.11% -3854.61% -8903.05%                 
      other income, net:
    		                          
      interest income
    		6,239,000 3,898,000 5,385,000 4,683,000 3,296,000 5,195,000 4,075,000 5,578,000 3,793,000 4,514,000 4,153,000 4,092,000 2,417,000 766,000 267,000 182,000 234,000 323,000 394,000 448,000 692,000 934,000 1,941,000 2,410,000 2,736,000 1,662,000 
      interest expense
    		-11,739,000 -37,637,000 -42,141,000 -29,821,000 -23,061,000 -22,937,000 -23,471,000 -20,268,000 -20,306,000 -20,594,000 -20,121,000 -19,990,000 -19,825,000 -20,279,000 -20,344,000 -15,134,000 -11,067,000 -10,839,000 -9,738,000 -10,962,000 -10,929,000 -10,754,000 -4,010,000 -3,040,000 -2,113,000 -1,941,000 
      noncash interest expense on deferred royalty obligations
    		-36,410,000                          
      gain on deconsolidation of subsidiaries
    		    52,027,000                      
      loss on extinguishments of debt
    		                          
      net income from equity method investments
    		-15,834,000 -20,189,000 -15,556,000 -16,695,000 -6,563,000                      
      other income
    		16,461,000 6,548,000 8,231,000 1,624,000 1,797,000 -632,000 9,483,000 21,778,000 -5,283,000 1,476,000 -601,000 4,560,000 6,331,000 -10,816,000 -7,575,000 28,284,000 -684,000 2,457,000 5,766,000 2,978,000 9,000 -1,827,000 474,000 -1,170,000 -26,000 -7,000 
      total other income
    		-41,283,000 -47,380,000 -65,236,000 -40,209,000 27,496,000 99,995,000 -36,503,000 7,088,000 -21,796,000 -14,604,000 -16,569,000 -11,338,000 -11,077,000 77,617,000 -27,652,000 13,332,000 -11,517,000 -8,059,000 -3,578,000 -7,536,000 -10,228,000 -11,647,000 -1,595,000 -5,513,000 -6,132,000 -5,016,000 
      income before income taxes
    		-186,482,000 -181,658,000                         
      benefit from income taxes
    		-1,545,000                          
      net income
    		-184,937,000 -183,758,000 -169,608,000 -267,389,000 -164,254,000 -75,544,000 -36,160,000 -170,328,000 -179,488,000 -160,703,000 -142,732,000 -140,570,000 -140,193,000 -2,559,000 -201,330,000 -152,282,000 -161,016,000 -102,074,000 -171,082,000 -135,025,000 -130,167,000 -136,214,000 -104,082,000 -84,151,000 -60,664,000  
      yoy
    		12.59% 143.25% 369.05% 56.98% -8.49% -52.99% -74.67% 21.17% 28.03% 6179.91% -29.11% -7.69% -12.93% -97.49% 17.68% 12.78% 23.70% -25.06% 64.37% 60.46% 114.57%      
      qoq
    		0.64% 8.34% -36.57% 62.79% 117.43% 108.92% -78.77% -5.10% 11.69% 12.59% 1.54% 0.27% 5378.43% -98.73% 32.21% -5.42% 57.74% -40.34% 26.70% 3.73% -4.44% 30.87% 23.68% 38.72%   
      net income margin %
    		   -4545.89% -6012.23% -3484.50% -17.13% -9760.92% -4387.39% -9792.99%                 
      net income attributable to redeemable convertible noncontrolling interests and noncontrolling interests
    		2,194,000 1,855,000 2,186,000 2,339,000 2,214,000 2,088,000 944,000 2,180,000 2,489,000  2,576,000 2,979,000 2,854,000  4,933,000 5,105,000 5,081,000 5,726,000 8,003,000 15,044,000 14,308,000 15,180,000 12,232,000 10,693,000 684,000 8,370,000 
      net income attributable to common stockholders of bridgebio
    		-182,743,000 -181,903,000 -167,422,000 -265,050,000 -162,040,000 -73,456,000 -35,216,000 -168,148,000 -176,999,000 -157,899,000 -140,156,000 -137,591,000 -137,339,000 -9,856,000 -196,397,000 -147,177,000 -155,935,000 -96,348,000 -163,079,000 -119,981,000 -115,859,000 -121,034,000 -91,850,000 -73,458,000 -59,980,000  
      net income per share
    		-0.95 -0.95 -0.88 -1.42 -0.86 -0.39 -0.2 -0.96 -1.08 -0.98 -0.92 -0.92 -0.93 -0.07 -1.35 -1.02 -1.06 -0.66 -1.18 -1.01 -0.98 -1.03 -0.78 -0.62 -0.51  
      weighted-average shares used for eps calculation
    		191,854,152 190,517,215 190,145,253 186,075,873 188,510,372 187,586,680 178,705,310 162,791,511 163,308,632 160,535,435 152,645,635 147,473,076 147,937,817 146,684,804 145,882,149 144,356,619 146,662,756 146,754,299 138,627,729 117,995,457 118,168,063 117,012,062 117,803,438 105,099,089 117,071,188  
      gain on deconsolidation of a subsidiary
    		     126,294,000                     
      losses on extinguishments of debt
    		                          
      income tax expense
    		 2,100,000                         
      cost of license and services revenue
    		  605,000                        
      loss on extinguishment of debt
    		  -21,155,000    -26,590,000                    
      revenue
    		   5,882,000 2,732,000 2,168,000 211,120,000 1,745,000 4,091,000 1,641,000                 
      yoy
    		   237.08% -33.22% 32.11%                     
      qoq
    		   115.30% 26.01% -98.97% 11998.57% -57.35% 149.30%                  
      cost of revenue
    		   2,084,000 598,000 598,000 598,000 598,000 598,000 599,000                 
      gross profit
    		   3,798,000 2,134,000 1,570,000 210,522,000 1,147,000 3,493,000 1,042,000                 
      yoy
    		   231.12% -38.91% 50.67%                     
      qoq
    		   77.98% 35.92% -99.25% 18254.14% -67.16% 235.22%                  
      gross margin %
    		   64.57% 78.11% 72.42% 99.72% 65.73% 85.38% 63.50%                 
      net income from equity method investment
    		     -7,925,000                     
      gain from sale of priority review voucher
    		             107,946,000             
      net income (income) attributable to redeemable convertible noncontrolling interests and noncontrolling interests
    		         2,804,000    -7,297,000             
      revenue:
    		                          
      product sales
    		           95,000   1,459,000 2,047,000 759,000 987,000         
      total revenue
    		          1,826,000 1,870,000 338,000 73,746,000 1,694,000 12,886,000 2,344,000 54,024,000         
      cost of license revenue and products sold
    		          651,000 647,000 739,000 700,000 1,348,000            
      license revenue
    		              235,000 10,839,000 1,585,000 53,037,000 462,000 122,000 8,127,000   13,819,000 26,741,000  
      cost of products sold
    		               1,172,000 1,454,000 109,000         
      operating expenses:
    		                          
      general and administrative
    		                  45,407,000 37,437,000 36,016,000 37,969,000 34,262,000 34,972,000 23,495,000 16,918,000 
      total operating expenses
    		                  167,966,000 127,611,000 128,066,000 124,567,000 102,487,000 92,457,000 81,273,000 69,249,000 
      cost of license revenue
    		                        2,500,000  
      share in net income of an equity method investment
    		                          
      income from ml bio asset acquisition
    		                        -416,000  
      income from pellepharm
    		                       -4,036,000 -6,589,000 -4,956,000 
      leo call option income
    		                       -253,000 276,000 226,000 
      net income and comprehensive loss
    		                         -74,265,000 
      net income and comprehensive loss attributable to bridgebio
    		                         -65,895,000 
      cumulative returns on redeemable convertible preferred units
    		                          
      net income attributable to redeemable founder units and redeemable common units
    		                         -65,895,000 
      net income per unit attributable to redeemable founder unitholders and redeemable common unitholders, basic and diluted
    		                         -3,460 
      total weighted-average redeemable founder units and redeemable common units used in computing net income per unit, basic and diluted
    		                         19,033,838,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.